The European Commission has approved teplizumab, a new treatment for people with type 1 diabetes, at a stage of the disease where diabetes has not yet clinically manifested.

This medication, marketed under the name Teizeild, serves to delay the progression to stage 3, which requires daily insulin treatment. Approved based on the clinical study TN-10, teplizumab demonstrated a median delay of two years in the onset of the clinical stage of the disease compared to placebo. The study included 76 participants, and the results showed that 57% of those treated remained in stage 2, compared to 28% in the placebo group. The safety profile was similar to previous studies, with the most common adverse reactions being transient lymphopenia and skin rashes.

Teplizumab is a monoclonal antibody that suppresses the immune response, allowing the body to produce insulin for a longer time. This treatment represents a breakthrough in the therapy of autoimmune type 1 diabetes.